차세대 조직 바이오마커 시장 : 규모, 점유율 및 동향 분석 보고서 - 제품별, 유형별, 기술별, 용도별, 최종 용도별, 지역별 부문 예측(2025-2030년)

Next Generation Tissue Biomarkers Market Size, Share & Trends Analysis Report By Product (Reagents & Assays, Instruments & Platforms), By Type (Genomic, Proteomic), By Technology, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,242,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,627,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,398,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

차세대 조직 바이오마커 시장 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 차세대 조직 바이오마커 시장 규모는 2030년까지 59억 8,000만 달러에 이를 것으로 예상되며, 예측 기간 동안 12.74%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.

만성 질환의 유병률 증가, 바이오마커 검출 기술의 기술적 진보, 개별화 의약품에 대한 수요 증가 등의 주요 촉진요인이 시장 성장의 요인이 되고 있습니다. 당뇨병, 암, 기타 자가면역 질환 등의 만성 질환의 발생률은 세계적으로 증가하고 있습니다.

차세대 조직 바이오마커를 검출하기 위한 기술 진보 증가가 시장의 성장을 뒷받침하고 있습니다. 일을 분석 할 수 있는 능력이 크게 향상되었습니다. 이 기술적 진보를 총칭하면 조직 바이오마커 탐색의 상황은 일변하고, 보다 정확한 진단, 맞춤 치료 전략, 환자 결과의 개선으로 이어집니다. 개별화된 의약품에 대한 수요 증가도 시장 성장의 주요 요인입니다.

바이오마커의 검출에 관해서는 에피유전체 연구 툴의 아리다 바이오사이언시스(AlidaBio)가 2025년 2월, EpiPlex 플랫폼의 본격적인 상업화를 정식으로 발표했습니다.

2025년 2월, 유전체 솔루션을 제공하는 바이오피델리티사는 폭넓은 응용을 기대할 수 있는 혁신적인 타겟 농축 기술인 Enspyre의 발매에 관한 상세를 발표했습니다.

2024년 9월, RNA 바이오마커 기업인 Genialis사는 다른 조직형 및 변이형에 걸쳐 KRAS 억제제(KRASi)에 대한 환자의 반응성과 임상적 유용성을 예측할 수 있는 최초의 바이오마커 알고리즘인 Genialis krasID의 발매를 발표했습니다. krasID는 화합물/MOA의 분화 및 선택과 같은 전임상 초기부터 임상시험까지 약제 개발 지침을 지원할 수 있습니다.

2024년 10월, 또 다른 신규 노화 세포 표적 분자가 개발되었습니다.

2021년 9월 Roche는 AVENIO Tumor Tissue CGP Kit의 출시를 발표했습니다. 이 새로운 키트는 Roche와 Foundation Medicine의 기존 CGP 포트폴리오를 강화하는 것으로 연구실이 사내에서 보다 광범위한 종양학 연구를 실시할 수 있게 됩니다.

차세대 조직 바이오마커 시장 : 분석 개요

• 제품별로는 시약 및 분석가 2024년에 55.97%의 최대 매출 점유율을 차지했습니다.
• 유형별로는 유전체 바이오마커의 부문이 2024년 시장을 독점했습니다. 마커는 예측기간 중에 가장 급성장이 예상됩니다.
• 기술별로, 차세대 시퀀싱 부문은 2024년에 가장 큰 수익 점유율로 시장을 독점했습니다. 공간 유전체학 생물학 부문은 2024-2030년간 가장 빠른 CAGR을 나타낼 것으로 예측되고 있습니다.
• 용도별로는 종양분야가 2024년 최대의 수익 점유율로 시장을 독점했습니다.
• 최종 용도별로 병원·참조 검사실 부문이 2024년에 최대의 수익 점유율을 획득하여 시장을 독점했습니다.

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 차세대 조직 바이오마커 시장 : 변동 요인, 동향 및 범위

• 시장 연관 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 차세대 조직 바이오마커 시장 : 분석 도구
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석

제4장 차세대 조직 바이오마커 시장 : 제품별 추정 및 동향 분석

• 부문 대시보드
• 차세대 조직 바이오마커 시장 : 제품별 변동 분석
• 차세대 조직 바이오마커 시장 규모와 동향 분석 : 제품별(2018-2030년)
• 시약 및 분석
• 기기 및 플랫폼
• 소프트웨어 및 AI

제5장 차세대 조직 바이오마커 시장 : 유형별 추정 및 동향 분석

• 시장 점유율 : 유형별(2024년, 2030년)
• 부문 대시보드
• 차세대 조직 바이오마커 시장 : 유형별 전망
• 시장 규모 예측과 동향 분석 : 유형별(2018-2030년)
• 게놈 바이오마커
• 프로테오믹 바이오마커
• 프로테오믹 바이오마커
• 후성 유전학적 바이오마커
• 전사체 바이오마커
• 대사체 바이오마커

제6장 차세대 조직 바이오마커 시장 : 기술별 추정 및 동향 분석

• 시장 점유율 : 기술별(2024년, 2030년)
• 부문 대시보드
• 차세대 조직 바이오마커 시장 : 제품별 변동 분석
• 차세대 조직 바이오마커 시장 규모와 동향 분석 : 제품별(2018-2030년)
• 면역조직화학
• 차세대 시퀀싱(NGS)
• 질량 분석(MS) 기반 프로테오믹스
• 공간 생물학 플랫폼
• 디지털 병리학 및 AI 분석
• 기타

제7장 차세대 조직 바이오마커 시장 : 용도별 추정 및 동향 분석

• 시장 점유율 : 용도별(2024년, 2030년)
• 부문 대시보드
• 차세대 조직 바이오마커 시장 : 용도별 변동 분석
• 차세대 조직 바이오마커 시장 규모와 동향 분석 : 용도별(2018-2030년)
• 종양학
• 동반진단
• 신약 발견 및 개발
• 신경학
• 기타

제8장 차세대 조직 바이오마커 시장 : 최종 용도의 추정 및 동향 분석

• 시장 점유율 : 최종 용도별(2024년, 2030년)
• 부문 대시보드
• 차세대 조직 바이오마커 시장 : 최종 용도별 변동 분석
• 차세대 조직 바이오마커 시장 규모와 동향 분석 : 최종 용도별(2018-2030년)
• 병원 및 참조 검사실
• 제약 및 생명공학 기업
• 학술 및 연구기관
• CRO(임상시험수탁기관)

제9장 차세대 조직 바이오마커 시장 : 지역별 추정 및 동향 분석

• 시장 점유율 분석 : 지역별(2024년, 2030년)
• 시장 대시보드 : 지역별
• 세계의 시장 현황 : 지역별
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제10장 경쟁 구도

• 최근 동향과 영향 분석 : 주요 시장 진출기업별
• 기업/경쟁의 분류
• 공급업체 상황
  • 주요 유통업체·채널 파트너 목록
  • 주요 고객
  • 주요 기업의 시장 점유율 분석(2024년)
  • Roche Diagnostics/Ventana Medical Systems
  • Agilent Technologies/Dako
  • Thermo Fisher Scientific
  • Leica Biosystems(Danaher Corporation)
  • Illumina
  • Qiagen
  • NeoGenomics
  • NanoString Technologies
  • Akoya Biosciences
  • Bio-Techne/ACD
  • Guardant Health

KTH

영문 목차

영문목차

Next Generation Tissue Biomarkers Market Growth & Trends:

The global next generation tissue biomarkers market size is anticipated to reach USD 5.98 billion by 2030 and is projected to grow at a CAGR of 12.74% during the forecast period, according to a new report by Grand View Research, Inc. Key driving factors such as increasing prevalence of chronic diseases, technological advancements in biomarker detection techniques, and rising demand for personalized medicines are responsible for market growth. There is a global increase in the incidence of chronic diseases such as diabetes, cancer, and other autoimmune diseases.

Increasing technological advancements for detecting next generation tissue biomarkers boost the growth of the market. The development of high throughput screening technologies such as next-generation sequencing (NGS) has significantly enhanced the ability to analyze genetic mutations and gene expression profiles in cancer tissues. Furthermore, liquid biopsies, high throughput screening technologies, epigenetic profiling, and microRNA-based biosensors are in practice for next generation tissue biomarker detection. Collectively, these technological advancements are transforming the landscape of tissue biomarker discovery, leading to more accurate diagnostics, personalized treatment strategies, and improved patient outcomes. AI and machine learning algorithms are being incorporated into digital pathology, automating the analysis of tissue images. The growing demand for personalized medicines is another key factor responsible for market growth. These personalized medicines are increasingly leveraging next-generation tissue biomarkers to tailor treatments to individual patients.

For the detection of biomarkers, in February 2025, Alida Biosciences (AlidaBio), a company in epigenomic research tools, officially announced the full commercial launch of its EpiPlex platform. This groundbreaking platform is the first to simultaneously detect and quantify multiple RNA modifications through short-read sequencing while also providing gene expression data.

In February 2025, Biofidelity, a provider of genomic solutions, unveiled details about the launch of Enspyre, an innovative target enrichment technology with a wide range of potential applications. A groundbreaking target enrichment technology that greatly improves next-generation sequencing (NGS) efficiency by selectively eliminating background DNA.

In September 2024, Genialis, an RNA biomarker company, announced the launch of Genialis krasID, the first biomarker algorithm capable of predicting patient response and clinical benefit to KRAS inhibitors (KRASi) across different tissue histologies and mutation types. Genialis krasID can assist in guiding drug development from early preclinical stages, such as compound/MOA differentiation and selection, to clinical trials.

Another novel senescent cell targeting molecules was developed in October 2024. Illumina, Inc., a company in DNA sequencing and array-based technologies, introduced its MiSeq i100 Series of sequencing systems today, offering unmatched benchtop speed and ease of use to enhance next-generation sequencing (NGS) in laboratories.

In September 2021, Roche announced the release of the AVENIO Tumor Tissue CGP Kit. This new kit enhances the existing CGP portfolio from Roche and Foundation Medicine, enabling laboratories to conduct more extensive oncology research in-house. The introduction of this kit will greatly increase global access to genomic profiling by offering an in-house solution for those unable to access our tests through centralized laboratories, the company stated.

Next Generation Tissue Biomarkers Market Report Highlights:

• Based on product, reagents and assays accounted for the largest revenue share of 55.97% in 2024. This segment is expected to see rapid expansion due to its broad applicability in biopharmaceutical research. A key driving factor is the growing need for early disease detection and diagnostics, which has resulted in high demand for accurate, reliable, and rapid diagnostics, contributing to market growth.
• Based on type, the genomic biomarker segment dominated the market in 2024 owing to the rising demand for innovative therapies, growing competition for early disease detection, and significant R&D investments. Metabolomic biomarkers are expected to grow fastest over the forecast period. Metabolomic biomarkers refer to specific metabolic changes or substances in the body that can be measured and used to identify disease states, predict disease risk, and monitor responses to treatments.
• Based on technology, the next generation sequencing segment dominated the market with the largest revenue share in 2024. Next Generation Sequencing (NGS) refers to the huge DNA sequencing methods that aid in genomic discovery. The spatial genomics biology segment is anticipated to witness growth at the fastest CAGR from 2024 to 2030. The advancements in genome editing tools, such as the CRISPR/Cas9 system, have facilitated spatial genomics biology adoption, driving market growth.
• Based on application, the oncology segment dominated the market with the largest revenue share in 2024. The growing demand for precision medicine drives the segment growth and targeted cancer therapies. Companion diagnostics are expected to grow fastest over the forecast period. The companion diagnostics market is experiencing significant product expansion, with new assays being developed for various cancer types, autoimmune diseases, and neurological disorders.
• Based on end use, the hospitals & reference labs segment dominated the market with the largest revenue share in 2024. Hospitals and reference labs are rapidly adopting next generation tissue biomarkers to enhance efficiency, accuracy, and accessibility. Contract research organizations are projected to grow significantly during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Technology
  • 1.2.3. Application
  • 1.2.4. Type
  • 1.2.5. End Use
  • 1.2.6. Regional scope
  • 1.2.7. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Application outlook
  • 2.2.4. Type outlook
  • 2.2.5. End Use outlook
  • 2.2.6. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Next Generation Tissue Biomarkers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rise of Precision Medicine and Companion Diagnostics
    • 3.2.1.2. Technological Advancements in Spatial Biology and NGS
    • 3.2.1.3. Expansion of Clinical Utility Across Disease Areas
    • 3.2.1.4. Growth in Digital Pathology and AI-Driven Analysis
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost of Multi-Omic Platforms and Reagents
    • 3.2.2.2. Data Privacy and Infrastructure Barriers in AI Adoption
• 3.3. Next Generation Tissue Biomarkers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Next Generation Tissue Biomarkers Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Next Generation Tissue Biomarkers Market: Product Movement Analysis
• 4.3. Next Generation Tissue Biomarkers Market Size & Trend Analysis, by product, 2018 to 2030 (USD Million)
• 4.4. Reagents & Assays
  • 4.4.1. Reagents & Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Instruments & Platforms
  • 4.5.1. Instruments & Platforms Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Software & AI
  • 4.6.1. Software & AI Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Next Generation Tissue Biomarkers Market: Type Estimates & Trend Analysis

• 5.1. Type Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Next Generation Tissue Biomarkers Market by Type Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Genomic Biomarkers
  • 5.5.1. Genomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Proteomic Biomarkers
  • 5.6.1. Proteomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Proteomic Biomarkers
  • 5.7.1. Proteomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Epigenetic Biomarkers
  • 5.8.1. Epigenetic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Transcriptomic Biomarkers
  • 5.9.1. Transcriptomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.10. Metabolomic Biomarkers
  • 5.10.1. Metabolomic Biomarkers Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Next Generation Tissue Biomarkers Market: Technology Estimates & Trend Analysis

• 6.1. Technology Market Share, 2024 & 2030
• 6.2. Segment Dashboard
• 6.3. Next Generation Tissue Biomarkers Market by Technology Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Immunohistochemistry
  • 6.5.1. Immunohistochemistry Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Next-Generation Sequencing (NGS)
  • 6.6.1. Next-Generation Sequencing (NGS) Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Mass Spectrometry (MS)-based Proteomics
  • 6.7.1. Mass Spectrometry (MS)-based Proteomics Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Spatial Biology Platforms
  • 6.8.1. Spatial Biology Platforms Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. Digital Pathology & AI Analysis
  • 6.9.1. Digital Pathology & AI Analysis Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.10. Others
  • 6.10.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Next Generation Tissue Biomarkers Market: Application Estimates & Trend Analysis

• 7.1. Application Market Share, 2024 & 2030
• 7.2. Segment Dashboard
• 7.3. Next Generation Tissue Biomarkers Market by Application Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. Oncology
  • 7.5.1. Oncology Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Companion Diagnostics
  • 7.6.1. Companion Diagnostics Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Drug Discovery & Development
  • 7.7.1. Drug Discovery & Development Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Neurology
  • 7.8.1. Neurology Market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. Others
  • 7.9.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Next Generation Tissue Biomarkers Market: End Use Estimates & Trend Analysis

• 8.1. End Use Market Share, 2024 & 2030
• 8.2. Segment Dashboard
• 8.3. Next Generation Tissue Biomarkers Market by End Use Outlook
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 8.5. Hospitals & Reference Labs
  • 8.5.1. Hospitals & Reference Labs Market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Pharma & Biotech Companies
  • 8.6.1. Pharma & Biotech Companies Market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Academic and Research Institutes
  • 8.7.1. Academic and Research Institutes Market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Contract Research Organizations (CROs)
  • 8.8.1. Contract Research Organizations (CROs) Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Next Generation Tissue Biomarkers Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. Global Regional Market Snapshot
• 9.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.5. North America
  • 9.5.1. North America
  • 9.5.2. U.S.
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/Reimbursement
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.3. Canada
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/Reimbursement
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5.4. Mexico
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework/Reimbursement
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 9.6. Europe
  • 9.6.1. Europe
  • 9.6.2. UK
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/Reimbursement
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.3. Germany
    • 9.6.3.1. Key country dynamics
    • 9.6.3.2. Regulatory framework/Reimbursement
    • 9.6.3.3. Competitive scenario
    • 9.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.4. France
    • 9.6.4.1. Key country dynamics
    • 9.6.4.2. Regulatory framework/Reimbursement
    • 9.6.4.3. Competitive scenario
    • 9.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.5. Italy
    • 9.6.5.1. Key country dynamics
    • 9.6.5.2. Regulatory framework/Reimbursement
    • 9.6.5.3. Competitive scenario
    • 9.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.6. Spain
    • 9.6.6.1. Key country dynamics
    • 9.6.6.2. Regulatory framework/Reimbursement
    • 9.6.6.3. Competitive scenario
    • 9.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.7. Norway
    • 9.6.7.1. Key country dynamics
    • 9.6.7.2. Regulatory framework/Reimbursement
    • 9.6.7.3. Competitive scenario
    • 9.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.8. Sweden
    • 9.6.8.1. Key country dynamics
    • 9.6.8.2. Regulatory framework/Reimbursement
    • 9.6.8.3. Competitive scenario
    • 9.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6.9. Denmark
    • 9.6.9.1. Key country dynamics
    • 9.6.9.2. Regulatory framework/Reimbursement
    • 9.6.9.3. Competitive scenario
    • 9.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 9.7. Asia Pacific
  • 9.7.1. Asia Pacific
  • 9.7.2. Japan
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/Reimbursement
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.3. China
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/Reimbursement
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.4. India
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/Reimbursement
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.5. Australia
    • 9.7.5.1. Key country dynamics
    • 9.7.5.2. Regulatory framework/Reimbursement
    • 9.7.5.3. Competitive scenario
    • 9.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.6. South Korea
    • 9.7.6.1. Key country dynamics
    • 9.7.6.2. Regulatory framework/Reimbursement
    • 9.7.6.3. Competitive scenario
    • 9.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7.7. Thailand
    • 9.7.7.1. Key country dynamics
    • 9.7.7.2. Regulatory framework/Reimbursement
    • 9.7.7.3. Competitive scenario
    • 9.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 9.8. Latin America
  • 9.8.1. Latin America
  • 9.8.2. Brazil
    • 9.8.2.1. Key country dynamics
    • 9.8.2.2. Regulatory framework/Reimbursement
    • 9.8.2.3. Competitive scenario
    • 9.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.8.3. Argentina
    • 9.8.3.1. Key country dynamics
    • 9.8.3.2. Regulatory framework/Reimbursement
    • 9.8.3.3. Competitive scenario
    • 9.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 9.9. MEA
  • 9.9.1. MEA
  • 9.9.2. South Africa
    • 9.9.2.1. Key country dynamics
    • 9.9.2.2. Regulatory framework/Reimbursement
    • 9.9.2.3. Competitive scenario
    • 9.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.3. Saudi Arabia
    • 9.9.3.1. Key country dynamics
    • 9.9.3.2. Regulatory framework/Reimbursement
    • 9.9.3.3. Competitive scenario
    • 9.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.4. UAE
    • 9.9.4.1. Key country dynamics
    • 9.9.4.2. Regulatory framework/Reimbursement
    • 9.9.4.3. Competitive scenario
    • 9.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.9.5. Kuwait
    • 9.9.5.1. Key country dynamics
    • 9.9.5.2. Regulatory framework
    • 9.9.5.3. Competitive scenario
    • 9.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
  • 10.3.3. Key company market share analysis, 2024
  • 10.3.4. Roche Diagnostics / Ventana Medical Systems
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Services benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Agilent Technologies / Dako
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Services benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Thermo Fisher Scientific
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Services benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. Leica Biosystems (Danaher Corporation)
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Services benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Illumina
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Services benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Qiagen
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Services benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. NeoGenomics
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Services benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. NanoString Technologies
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Services benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Akoya Biosciences
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Services benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. Bio-Techne / ACD
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Services benchmarking
    • 10.3.13.4. Strategic initiatives
  • 10.3.14. Guardant Health
    • 10.3.14.1. Company overview
    • 10.3.14.2. Financial performance
    • 10.3.14.3. Services benchmarking
    • 10.3.14.4. Strategic initiatives

관련자료